Designation of Nitisinone as an orphan drug by Orpharma Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods in Australia, ensuring their safety, quality, and efficacy. The Act was introduced to address the need for a comprehensive framework governing the importation, manufacture, supply, and advertising of therapeutic goods. Enacted by the Commonwealth Parliament, the policy objective of the Act is to protect public health by maintaining high standards for therapeutic goods. In a specific instance, the Therapeutic Goods Administration, acting under the authority of the Therapeutic Goods Regulations 1990, designated nitisinone (Nitisinone Tablets) as an orphan drug on 28 November 2016. This designation was made to facilitate the availability of orphan drugs, which are intended for the treatment of rare conditions, in this case, hereditary tyrosinaemia type 1, thereby addressing a significant gap in the therapeutic options for patients with this rare disorder.

Scope and Application

The Therapeutic Goods Act 1989, under the auspices of the Therapeutic Goods Administration within the Commonwealth of Australia, applies to the designation of therapeutic goods, including drugs, with a specific focus on orphan drugs like nitisinone (Nitisinone Tablets) which are designated for the treatment of rare medical conditions. In this instance, nitisinone is designated for the treatment of patients with hereditary tyrosinaemia type 1, indicating the Act’s application to pharmaceuticals intended for rare diseases affecting a small patient population. The Act governs the therapeutic use of these drugs, ensuring that they are appropriately classified, approved, and monitored for safety and efficacy. The geographic and jurisdictional reach of the Act is national, applying uniformly across all states and territories of Australia, thereby ensuring consistent standards and regulations are upheld throughout the country. This designation is made under the authority of the Delegate of the Secretary, as specified in the Therapeutic Goods Regulations 1990, and does not include any explicit exclusions or exemptions beyond the criteria for orphan drug status. The Act’s provisions are further extended through subordinate instruments which detail the specific regulatory requirements and processes for the approval and monitoring of therapeutic goods.

Key Provisions

The key provision of this legislative instrument, under the Therapeutic Goods Act 1989, designates nitisinone (Nitisinone Tablets) as an orphan drug for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine (s16J of the Therapeutic Goods Regulations 1990). This designation recognises the rarity of the disease and the importance of making treatments available for patients who might otherwise not have access to such therapies. The therapeutic use of nitisinone in this context is intended to help manage the symptoms and improve the quality of life for those affected by this rare genetic disorder. The specific form of the drug, nitisinone (Nitisinone Tablets), is indicated for this use, which means that this particular formulation is recognised for its intended therapeutic purpose. The designation of nitisinone as an orphan drug imposes certain obligations on the parties involved. Primarily, the sponsor of the drug, Orpharma Pty Ltd, must ensure that the drug meets the specified criteria for orphan drug designation, including the rarity of the condition it treats and the lack of alternative treatments. Additionally, Orpharma Pty Ltd must comply with all relevant regulatory requirements, including those related to the manufacturing, quality, and safety of the drug. This designation also implies that there may be certain incentives or expedited processes available to the sponsor to facilitate the development and availability of the drug, such as priority review by regulatory authorities and potential financial incentives. Under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990, there are potential civil and criminal consequences for breaches of the provisions related to orphan drug designation. For example, if the sponsor fails to comply with the regulatory requirements for the manufacture, quality, and safety of the drug, they could face enforcement actions, including fines and other penalties. In more serious cases, criminal charges could be brought against individuals responsible for non-compliance, potentially resulting in substantial fines or imprisonment. The specific penalties depend on the nature and severity of the breach, but the regulations are designed to ensure that therapeutic goods meet high standards of safety and efficacy, thereby protecting public health.